Download MendeleyExploring the Existing Drug Space for Novel pTyr Mimetic and SHP2 Inhibitors.
He, R., Yu, Z.H., Zhang, R.Y., Wu, L., Gunawan, A.M., Lane, B.S., Shim, J.S., Zeng, L.F., He, Y., Chen, L., Wells, C.D., Liu, J.O., Zhang, Z.Y.(2015) ACS Med Chem Lett 6: 782-786
- PubMed: 26191366
- DOI: https://doi.org/10.1021/acsmedchemlett.5b00118
- Primary Citation of Related Structures:
4RDD - PubMed Abstract:
Protein tyrosine phosphatases (PTPs) are potential therapeutic targets for many diseases. Unfortunately, despite considerable drug discovery efforts devoted to PTPs, obtaining selective and cell permeable PTP inhibitors remains highly challenging. We describe a strategy to explore the existing drug space for previously unknown PTP inhibitory activities. This led to the discovery of cefsulodin as an inhibitor of SHP2, an oncogenic phosphatase in the PTP family. Crystal structure analysis of SHP2 interaction with cefsulodin identified sulfophenyl acetic amide (SPAA) as a novel phosphotyrosine (pTyr) mimetic. A structure-guided and SPAA fragment-based focused library approach produced several potent and selective SHP2 inhibitors. Notably, these inhibitors blocked SHP2-mediated signaling events and proliferation in several cancer cell lines. Thus, SPAA may serve as a new platform for developing chemical probes for other PTPs.
Organizational Affiliation:
Department of Biochemistry and Molecular Biology and Chemical Genomics Core Facility, Indiana University School of Medicine , 635 Barnhill Drive, Indianapolis, Indiana 46202, United States.
